Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

Transplant Rev (Orlando). 2016 Jul;30(3):119-43. doi: 10.1016/j.trre.2016.04.001. Epub 2016 Apr 29.


Cytomegalovirus (CMV) infection remains a major complication of solid organ transplantation. Because of management of CMV is variable among transplant centers, in 2011 the Spanish Transplantation Infection Study Group (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) developed consensus guidelines for the prevention and treatment of CMV infection in solid organ transplant recipients. Since then, new publications have clarified or questioned the aspects covered in the previous document. For that reason, a panel of experts revised the evidence on CMV management, including immunological monitoring, diagnostics, prevention, vaccines, indirect effects, treatment, drug resistance, immunotherapy, investigational drugs, and pediatric issues. This document summarizes the recommendations.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus Infections / drug therapy*
  • Humans
  • Monitoring, Immunologic
  • Organ Transplantation
  • Practice Guidelines as Topic
  • Transplant Recipients*


  • Antiviral Agents